Literature DB >> 8364931

A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53.

T Mukhopadhyay1, J A Roth.   

Abstract

Codon 248 in domain iv of the highly conserved region of the p53 gene is a frequent site of mutations associated with sporadic cancers and the familial cancer syndrome (Li-Fraumeni syndrome). Therefore, a characterization of the functional significance of a codon 248 mutation is of interest. We used antisense RNA methodology to study the role of the wild-type and mutated p53 gene in cell growth and tumorigenesis. We introduced wild-type p53 complementary DNA in sense or antisense orientation under control of a beta-actin promoter into human non-small cell lung cancer cell line H322a which has a codon 248 mutation (G to T) and WTH226b which has wild type p53. The biological properties and p53 expression of stable G418-resistant clones were analyzed. We observed that in both cell lines antisense RNA expression significantly reduced p53 mRNA and protein production; it also caused increases in growth rate in cell cultures and in tumorigenicity in nu/nu mice for both cell types, suggesting that the mechanism by which p53 suppresses cell proliferation and tumorigenesis is not always abrogated by a codon 248 mutation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364931

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination.

Authors:  S Nakamura; J A Roth; T Mukhopadhyay
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database.

Authors:  Lyubov E Salnikova
Journal:  Neuromolecular Med       Date:  2014-01-31       Impact factor: 3.843

Review 3.  The potential for gene therapy in pancreatic cancer.

Authors:  M J Humphreys; W Greenhalf; J P Neoptolemos; P Ghaneh
Journal:  Int J Pancreatol       Date:  1999-08

Review 4.  Reflections on viruses and cancer.

Authors:  C Darcel
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

Review 5.  Modulation of oncogene and tumor-suppressor gene expression: a novel strategy for cancer prevention and treatment.

Authors:  J A Roth
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

6.  The over-expression of p53 H179Y residue mutation causes the increase of cyclin A1 and Cdk4 expression in HELF cells.

Authors:  Di Yang; Yitao Qi; Qian Chen; Zhiqin Wang; Xi Jin; Jie Gao; Juanling Fu; Xilong Xiao; Zongcan Zhou
Journal:  Mol Cell Biochem       Date:  2007-05-26       Impact factor: 3.396

7.  Wilms' tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck.

Authors:  Xingru Li; Sofia Ottosson; Sihan Wang; Emma Jernberg; Linda Boldrup; Xiaolian Gu; Karin Nylander; Aihong Li
Journal:  BMC Cancer       Date:  2015-05-01       Impact factor: 4.430

8.  p53 mutations and overexpression in locally advanced breast cancers.

Authors:  A Faille; P De Cremoux; J M Extra; G Linares; M Espie; E Bourstyn; A De Rocquancourt; S Giacchetti; M Marty; F Calvo
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

9.  Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.

Authors:  C M Barton; N R Lemoine
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

10.  Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage postmenopausal patients with ER-positive breast cancer.

Authors:  Xiao-Qing Jia; Qi Hong; Jing-Yi Cheng; Jian-Wei Li; Yu-Jie Wang; Miao Mo; Zhi-Min Shao; Zhen-Zhou Shen; Guang-Yu Liu
Journal:  Onco Targets Ther       Date:  2015-03-03       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.